(RTTNews) - Several biotech stocks made sharp moves in after-hours trading on Thursday, September 11, 2025, driven by clinical updates, strategic pivots, and rebranding efforts. Here's a quick look at ...
Hosted on MSN
Exicure announces near-term strategic priorities
Exicure’s (XCUR) ongoing Phase 2 study is a randomized, open-label, multicenter trial evaluating burixafor, a small molecule CXCR4 antagonist, in autologous stem cell transplant for multiple myeloma.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback